Outlook Therapeutics, Inc. financial data

Symbol
OTLK on Nasdaq
Location
Iselin, NJ
Fiscal year end
30 September
Latest financial report
10-K - Q3 2025 - 19 Dec 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 48% % -41%
Quick Ratio 9.4% %
Debt-to-equity -151% % -0.66%
Return On Equity 164% % 72%
Return On Assets -324% % -68%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64,114,399 shares 157%
Common Stock, Shares, Outstanding 53,887,233 shares 125%
Entity Public Float $26,900,000 USD -85%
Common Stock, Value, Issued $538,873 USD 125%
Weighted Average Number of Shares Outstanding, Basic 34,796,120 shares 88%
Weighted Average Number of Shares Outstanding, Diluted 34,796,120 shares 88%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $1,505,322 USD
Research and Development Expense $27,180,640 USD -35%
General and Administrative Expense $38,646,594 USD 50%
Operating Income (Loss) $67,061,666 USD 6.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $20,152,502 USD -145%
Income Tax Expense (Benefit) $2,800 USD 0%
Net Income (Loss) Attributable to Parent $62,424,863 USD 17%
Earnings Per Share, Basic -1.79 USD/shares 56%
Earnings Per Share, Diluted -1.79 USD/shares 56%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $8,083,085 USD -46%
Accounts Receivable, after Allowance for Credit Loss, Current $1,490,931 USD
Inventory, Net $3,338,404 USD
Assets, Current $17,388,969 USD -37%
Operating Lease, Right-of-Use Asset $225,508 USD -18%
Other Assets, Noncurrent $417,523 USD -5%
Assets $18,584,183 USD -36%
Accounts Payable, Current $10,192,388 USD 28%
Employee-related Liabilities, Current $1,437,049 USD 42%
Accrued Liabilities, Current $5,314,320 USD 64%
Liabilities, Current $45,814,605 USD 7.7%
Operating Lease, Liability, Noncurrent $188,801 USD -24%
Liabilities $50,771,844 USD -50%
Retained Earnings (Accumulated Deficit) $605,709,763 USD -11%
Stockholders' Equity Attributable to Parent $32,187,661 USD 56%
Liabilities and Equity $18,584,183 USD -36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,967,335 USD 16%
Net Cash Provided by (Used in) Financing Activities $1,742,373 USD
Common Stock, Shares Authorized 260,000,000 shares 0%
Common Stock, Shares, Issued 53,887,233 shares 125%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $9,224,962 USD 29%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8,083,085 USD -46%
Deferred Tax Assets, Valuation Allowance $145,880,866 USD 5.1%
Deferred Tax Assets, Gross $145,928,541 USD 5.1%
Operating Lease, Liability $247,698 USD -17%
Lessee, Operating Lease, Liability, to be Paid $295,674 USD -21%
Operating Lease, Liability, Current $58,897 USD 16%
Lessee, Operating Lease, Liability, to be Paid, Year Two $81,817 USD 2.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $80,730 USD 3.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.099 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $47,976 USD -36%
Lessee, Operating Lease, Liability, to be Paid, Year Three $83,680 USD 2.3%
Deferred Tax Assets, Operating Loss Carryforwards $110,272,674 USD 7.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $300,000 USD -84%
Lessee, Operating Lease, Liability, to be Paid, Year Four $49,447 USD -41%
Operating Lease, Payments $19,329 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $47,675 USD -38%
Share-based Payment Arrangement, Expense $8,859,896 USD 65%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%